{"id":"nvx-cov2515","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Myalgia"},{"rate":"25-35","effect":"Headache"},{"rate":"10-20","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses recombinant nanoparticle technology to display the spike protein of SARS-CoV-2, combined with an adjuvant (Matrix-M) to enhance immunogenicity. This approach triggers both humoral and cellular immune responses, with the formulation designed to provide protection against emerging variants of concern including Omicron lineages.","oneSentence":"NVX-CoV2515 is a recombinant protein subunit vaccine that presents the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19 variants.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:45.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults (variant-specific booster formulation)"}]},"trialDetails":[{"nctId":"NCT05372588","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-05-25","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":1340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omicron BA.1 SARS-CoV-2 rS /Matrix-M Adjuvant"],"phase":"phase_3","status":"active","brandName":"NVX-CoV2515","genericName":"NVX-CoV2515","companyName":"Novavax","companyId":"novavax","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NVX-CoV2515 is a recombinant protein subunit vaccine that presents the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19 variants. Used for COVID-19 prevention in adults (variant-specific booster formulation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}